{"cdcTestId":"2021-0040","testcaseName":"3rd dose of Pfizer Covid-19 Vaccine administered 5 mos after previous dose ","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-09-05T00:00:00","patient":{"dob":"2006-04-28T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2021-11-14T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-04-01T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-09-01T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"4","earliestDate":"2022-10-27T00:00:00","recommendedDate":"2022-10-27T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2021-11-14T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-04-01T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-09-01T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T10:56:04.817","generalDescription":"This test case describes when a patient that is 16 years is administered the third dose of the Pfizer Covid-19 vaccine at 5 months after the second dose, that the dose is valid. Another dose should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated test case Assessment Date to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group."}